Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Zeria Pharmaceutical30 enrolled

Overview

To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Pancreatic Cancer

Interventions

Z-360DRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with unresectable locally advanced or metastatic pancreatic cancer * KPS \> 70% * Life expectancy of at least 3 months Exclusion Criteria: * received previous chemotherapy for the current indication * received previous radiotherapy for the current indication * Currently receiving chemotherapy

Locations (1)

Royal Free Hospital

London, United Kingdom

Outcomes

Primary Outcomes

Safety, Pharmacokinetics

Secondary Outcomes

Tumour shrinkage, Tumour objective response rate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.